The University of Chicago Header Logo

Connection

James Howard Tonsgard to Time Factors

Back to Details
This is a "connection" page, showing publications James Howard Tonsgard has written about Time Factors.
James Howard Tonsgard
Connection Strength
0.038
Time Factors
  1. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.
    View in: PubMed
    Score: 0.026
  2. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009 Aug 15; 15(16):5032-5039.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.